
A scanning electron micrograph of human sperm stuck together and immobilized by an antisperm antibody.
University of North Carolina Eshelman School of Pharmacy engineer ultra-potent sperm-binding monoclonal antibodies as option for affordable, non-hormonal female contraception
Scientists at the University of North Carolina at Chapel Hill are using the precision targeting of monoclonal antibodies for a new type of female contraception.
Monoclonal antibodies are known for their ability to fight off invading germs and are used to treat and prevent everything from cancer to COVID-19. Scientists are now looking at a new mission for antibodies: immobilizing sperm before it can reach an egg.
Carolina researchers have engineered ultra-potent antibodies that, during animal testing, effectively trapped and blocked more than 99.9% of human sperm. The promising study results published in Science Translational Medicine suggest contraceptives based on antibodies may offer women a non-hormonal option to prevent pregnancy.
“Many women avoid hormonal contraception because of real and perceived side effects,” said Samuel Lai, professor in the Division of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy.
These effects can include irregular bleeding, nausea, depression, weight gain and migraines. And for some women estrogen-based hormonal contraception can be harmful.
“There’s a major unmet need for alternative, non-hormonal contraceptives for women,” said Lai.
Antibodies as line of defense
Nearly half of all pregnancies in the United States are unintended, and Lai is among scientists across the country who are advancing the idea of using anti-sperm antibodies for contraception.
“We were inspired by infertility that occurs in some women who develop antibodies against their partner’s sperm,” said study first author Bhawana Shrestha, a doctoral student in the Department of Microbiology and Immunology at the UNC School of Medicine and graduate research assistant at the school of pharmacy.
The antibody they’re testing was isolated from an infertile woman and targets a unique surface antigen present on human sperm. When it’s added to sperm, the sperm quickly clump together.
“Using our highly multivalent IgG platform, we engineered antibodies that were more than 10 to 16 times more potent at agglutinating sperm and reducing sperm permeation through mucus than the best-known antibody,” she said.
Researchers explored the effect of antibodies in sheep, which have reproductive tracts similar to human females. At a high dose of 333 micrograms of antibody, both naturally occurring antibodies and the newly engineered antibodies, effectively stopped all human sperm motility, and at a low dose of 33.3 micrograms, the modified antibodies, but not the original ones, trapped 97% to 99% of sperm.
Next step: clinical trials
But monoclonal antibodies are known as expensive drugs, which puts their usefulness as an affordable contraceptive up in the air.
However, researchers believe that by increasing the potency, much lower doses of the multivalent antibodies may be needed for effective contraception.
“We think these second-generation molecules will provide not only greater potency but will translate to lower costs that make the approach cost-effective,” said Lai.
Mucommune, a startup spun out of the Lai Lab, has licensed the molecule for development of an antibody-based contraceptive. The company will focus on safety and manufacturing to prepare for human clinical trials that could start in 2023.
The team is working on incorporating the antibodies into an intravaginal ring that steadily releases the antibodies, or a dissolvable film placed in the vagina where it spreads antibodies before sex.
“By avoiding exogenous hormones and creating a women-controlled contraceptive method, we believe the antibodies developed here could meet the contraceptive needs for millions of women, help to reduce the number of unintended pregnancies and alleviate the health care costs of unintended pregnancies which some estimate to be in excess of $20 billion a year,” Lai said.
Original Article: Carolina scientists developing contraceptive that stops sperm in its tracks
More from: University of North Carolina at Chapel Hill | University of Texas Medical Branch | Boston University School of Medicine
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Non-hormonal female contraception
- Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)on January 12, 2023 at 5:36 am
Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that female telehealth leader Favor is now a specialty pharmacy provider of Phexxi® (lactic acid, citric acid and potassium bitartrate).
- 'Contraception Still a Woman's Duty': Why Men in TN Don't Turn Up for Vasectomyon January 6, 2023 at 9:01 am
The Tamil Nadu Family Welfare and Health Department devised campaigning strategies in 2022 to bust myths about male sterilisation – vasectomy – but data shows that there has been very little ...
- More women seek permanent contraception after Supreme Court abortion decisionon January 5, 2023 at 8:17 am
I had an aversion to hormonal birth control and serious side effects when I tried using a non-hormonal IUD [intrauterine ... Sinai in Los Angeles. More women like Quezada are asking about ...
- End of Roe v. Wade May Have More Women Opting for Permanent Contraceptionon January 5, 2023 at 7:51 am
I had an aversion to hormonal birth control and serious side effects when I tried using a non-hormonal IUD [intrauterine ... Sinai in Los Angeles. More women like Quezada are asking about ...
- Why is there still no male birth control pill?on January 5, 2023 at 6:04 am
Currently, that role often defaults to women, but male birth control pills will provide couples in heterosexual relationships with more choice. There are also non-hormonal options being tested ...
Go deeper with Google Headlines on:
Non-hormonal female contraception
[google_news title=”” keyword=”non-hormonal female contraception” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Sperm-binding monoclonal antibodies
- Before going to fight, many Ukrainians are freezing their spermon January 10, 2023 at 9:39 pm
But she had prepared for the eventuality. Now she intends to raise a family alone using sperm the couple froze on one of Vitaly’s two rotations back home. In an emotional appeal on social media ...
- Just 4% of Men Who Apply as Sperm Donors Are Acceptedon January 10, 2023 at 6:21 am
Just 4% of Men Who Apply as Sperm Donors Are Accepted By Dennis Thompson HealthDay Reporter TUESDAY, Jan. 10, 2023 (HealthDay News) -- Sperm donation is apparently a grueling and exacting process ...
- Think you got this, lads? Only four in 100 would-be sperm donors make the cut. Disease, unhealthy living and low-grade semen see many disqualifiedon January 9, 2023 at 1:41 pm
While many men believe they have what it takes to be a Sperm Donor, less than four in 100 who apply to donate end up having their samples frozen and used, researchers have revealed. A University ...
- Fewer than 4 in 100 men accepted to be sperm donors, finds studyon January 9, 2023 at 9:57 am
Fewer than 4 in 100 men who apply to be sperm donors reach the end of the process and have samples frozen and released for treatments, according to a new study. A European team of researchers led ...
- Britain imports most of its sperm – so scientists found out who it comes fromon January 9, 2023 at 4:24 am
It turns out that most of the UK’s sperm comes from the United States and Denmark (Credit: Getty / metro.co.uk) The UK relies on men from other countries to send us their sperm. Figures released ...
Go deeper with Google Headlines on:
Sperm-binding monoclonal antibodies
[google_news title=”” keyword=”sperm-binding monoclonal antibodies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]